Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020
August 26 2020 - 9:30AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage
biopharmaceutical company seeking to discover and develop
innovative medicines in areas of significant unmet medical need
with a current focus on breast cancer and COVID-19, today announces
that Dr. Steven Quay, Atossa’s President and Chief Executive
Officer, will give a virtual corporate presentation at the LD Micro
500 taking place online on Friday September 4, 2020 at 9:00 AM ET
followed by a live Q&A session with registered investors and
other conference attendees.
Webcast link:
https://www.webcaster4.com/Webcast/Page/2019/36654
In addition, Dr. Quay will be available for virtual one-on-one
meetings from September 1-4, 2020. To schedule a meeting
please contact Eric Lahiji at eric@ldmicro.com.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to discover and develop innovative medicines in
areas of significant unmet medical need with a current focus on
breast cancer and COVID-19. For more information, please visit
www.atossatherapeutics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
interim and final clinical results, actions and inactions by the
FDA, the outcome or timing of regulatory approvals needed by Atossa
including those needed to commence studies of AT-H201, AT-301 and
Endoxifen, lower than anticipated rate of patient enrollment,
estimated market size of drugs under development, the safety and
efficacy of Atossa’s products, performance of clinical research
organizations and investigators, obstacles resulting from
proprietary rights held by others such as patent rights, whether
reduction in Ki-67 or any other result from a neoadjuvant study is
an approvable endpoint for oral Endoxifen, and other risks detailed
from time to time in Atossa’s filings with the Securities and
Exchange Commission, including without limitation its periodic
reports on Form 10-K and 10-Q, each as amended and supplemented
from time to time.
Company Contact: Atossa Therapeutics, Inc. Kyle Guse CFO and
General Counsel Office: 866 893-4927 kyle.guse@atossainc.com
Investor Relations Contact: Core IROffice:(516)
222-2560ir@atossainc.com
Source: Atossa Therapeutics, Inc.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024